UnitedHealth Group raised its 2026 adjusted earnings floor to at least $20.50 a share after third-quarter profit beat Wall Street expectations and its medical care ratio came in about 1.5 percentage points better than analysts had expected.The health insurer reported third-quarter revenue of $112.7 billion and adjusted earnings of $4.69 a share, compared with the $4.14 average estimate compiled by LSEG. GAAP earnings were $4.56 a share.The new full-year adjusted earnings outlook of at least $20.50 is above the entire $19.50-to-$20.00 range UnitedHealth gave investors in July.The initial stock reaction did not hold. UnitedHealth shares traded as high as $399.88 after the report but had fallen to $376.61 at 3:28 p.m. ET, down 0.51% from Monday’s close of $378.52.
The 88.4% Medical Care Ratio Was the Number Investors Were Waiting For
The standout figure was UnitedHealth’s medical care ratio, which fell to 88.4% in the third quarter from 89.9% a year earlier.StreetAccount had expected 89.9%, meaning the reported ratio was around 150 basis points better than consensus. The ratio measures the share of premium revenue consumed by medical costs, so a lower result generally leaves more room for operating profit.That metric has been central to the UnitedHealth investment case after elevated healthcare utilization repeatedly pressured margins across Medicare Advantage and other insurance products.UnitedHealth attributed the improvement to medical cost management, changes to benefit design, pricing discipline and changes in how care is delivered.There is, however, an important qualification. The 88.4% figure included $610 million of favorable prior-period reserve development related to services provided earlier in 2026. That means claims for earlier periods ultimately developed more favorably than UnitedHealth had previously estimated, reducing reported medical costs in the quarter.StreetAccount said the company still appeared to beat expectations even excluding that reserve benefit, but the $610 million contribution is significant when assessing how much of the improvement can be carried forward into future quarters.
UnitedHealth Is Not Saying the Medical Cost Problem Is Over
Management was notably more cautious than the headline ratio might suggest.Chief Financial Officer Wayne DeVeydt said UnitedHealthcare’s performance reflected better pricing, medical cost management and care-delivery changes, but added that the company remains cautious around elevated utilization, particularly in risk-based businesses where demand typically increases during the second half of the year.UnitedHealthcare CEO Tim Noel went further, saying costs remain “stubbornly high” across healthcare, particularly in specialty pharmacy and acute-care intensity.Management also said care intensity remains above historical norms even though recent trends are becoming more stable. Commercial medical-cost trends are running above the company’s original 11% expectation, with pressure from specialty drugs, clinician pricing and costs associated with the No Surprises Act dispute process.That makes the quarter less a declaration that the cost cycle has been fixed than evidence that UnitedHealth is managing it better.The distinction matters for a stock whose valuation has repeatedly moved on medical-cost assumptions. FinanceFeeds previously tracked the uncertainty around the insurer in its UnitedHealth share-price recovery analysis, after the stock’s earlier collapse pushed investors to reassess the company’s earnings outlook and Medicare exposure.
Operating Profit Rose Even as Revenue Slipped
UnitedHealth generated $6.6 billion of operating earnings in the third quarter, up from $4.3 billion a year earlier, despite consolidated revenue slipping from $113.2 billion to $112.7 billion.UnitedHealthcare revenue fell to $86.3 billion from $87.1 billion, while operating earnings rose to $2.8 billion from $1.8 billion. The unit served 48.3 million people during the quarter.The membership base has also been deliberately reduced in some areas as UnitedHealth prioritizes profitability. Reuters reported that 935,000 members have exited its Medicare Advantage business since the end of 2025, alongside declines in employer-sponsored and Medicaid enrollment.Optum also contributed to the improvement, with management pointing to stronger execution in Optum Health and efficiency gains across technology and operations.
The New $20.50 Floor Also Sets Up the 2027 Debate
DeVeydt described the new $20.50 adjusted earnings floor as a base from which the company can grow and said current Wall Street estimates for 2027 may be too low.UnitedHealth continues to target long-term earnings growth of 13% to 16%, with management saying the lower end of that range is a reasonable starting point for thinking about next year.Investors have already shown a willingness to buy the stock during periods of extreme weakness. FinanceFeeds reported earlier that UnitedHealth was the most heavily bought U.S. stock among Saxo’s UK clients during May, with 81% of trades on the buy side during the earlier turnaround attempt.Tuesday’s price action shows that stronger earnings alone are not enough to settle the argument. The stock initially rallied after the beat and guidance increase, then gave back those gains during regular trading.The earnings floor is higher and the medical care ratio is clearly better. But the $610 million reserve benefit and management’s own warning that healthcare utilization remains elevated mean investors still have to decide how much of the third-quarter improvement represents a durable change in UnitedHealth’s underlying cost trend.
